These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 9731558)

  • 1. Effects of propranolol on the hepatic hemodynamic response to physical exercise in patients with cirrhosis.
    Bandi JC; García-Pagán JC; Escorsell A; François E; Moitinho E; Rodés J; Bosch J
    Hepatology; 1998 Sep; 28(3):677-82. PubMed ID: 9731558
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduction of variceal pressure by propranolol: comparison of the effects on portal pressure and azygos blood flow in patients with cirrhosis.
    Feu F; Bordas JM; Luca A; García-Pagán JC; Escorsell A; Bosch J; Rodés J
    Hepatology; 1993 Nov; 18(5):1082-9. PubMed ID: 8225212
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Daily variation in portal blood flow and the effect of propranolol administration in a randomized study of patients with cirrhosis.
    Alvarez D; de las Heras M; Abecasis R; Terg R; Gerona S; Albornoz L; Galdame O; Torres J; Mastai R
    Hepatology; 1997 Mar; 25(3):548-50. PubMed ID: 9049196
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial.
    Abraldes JG; Albillos A; Bañares R; Turnes J; González R; García-Pagán JC; Bosch J
    Gastroenterology; 2009 May; 136(5):1651-8. PubMed ID: 19208350
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Portal pressure response to losartan compared with propranolol in patients with cirrhosis.
    De BK; Bandyopadhyay K; Das TK; Das D; Biswas PK; Majumdar D; Mandal SK; Ray S; Dasgupta S
    Am J Gastroenterol; 2003 Jun; 98(6):1371-6. PubMed ID: 12818283
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Carvedilol, a new nonselective beta-blocker with intrinsic anti- Alpha1-adrenergic activity, has a greater portal hypotensive effect than propranolol in patients with cirrhosis.
    Bañares R; Moitinho E; Piqueras B; Casado M; García-Pagán JC; de Diego A; Bosch J
    Hepatology; 1999 Jul; 30(1):79-83. PubMed ID: 10385642
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hemodynamic response to propranolol in patients with recurrent hepatitis C virus-related cirrhosis after liver transplantation: a case-control study.
    Schepis F; Vukotic R; Berzigotti A; Carrión JA; Forns X; Abraldes JG; García-Valdecasas JC; Navasa M; García-Pagán JC; Bosch J
    Liver Transpl; 2013 Apr; 19(4):450-6. PubMed ID: 23408436
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Octreotide enhances portal pressure reduction induced by propranolol in cirrhosis: a randomized, controlled trial.
    Vorobioff JD; Ferretti SE; Zangroniz P; Gamen M; Picabea E; Bessone FO; Reggiardo V; Diez AR; Tanno M; Cuesta C; Tanno HE
    Am J Gastroenterol; 2007 Oct; 102(10):2206-13. PubMed ID: 17608776
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of beta-2 adrenergic receptor gene polymorphism on the hemodynamic response to propranolol in patients with cirrhosis.
    Turnes J; Hernández-Guerra M; Abraldes JG; Bellot P; Oliva R; García-Pagán JC; Bosch J
    Hepatology; 2006 Jan; 43(1):34-41. PubMed ID: 16374847
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of hyperdynamic circulation and response to β-blockers in compensated cirrhosis with portal hypertension.
    Villanueva C; Albillos A; Genescà J; Abraldes JG; Calleja JL; Aracil C; Bañares R; Morillas R; Poca M; Peñas B; Augustin S; Garcia-Pagan JC; Pavel O; Bosch J
    Hepatology; 2016 Jan; 63(1):197-206. PubMed ID: 26422126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the short-term effects of mepindolol and propranolol on splanchnic and systemic haemodynamics in patients with cirrhosis.
    Braillon A; Calès P; Lebrec D
    Int J Clin Pharmacol Res; 1985; 5(4):223-8. PubMed ID: 4055165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute hemodynamic response to beta-blockers and prediction of long-term outcome in primary prophylaxis of variceal bleeding.
    Villanueva C; Aracil C; Colomo A; Hernández-Gea V; López-Balaguer JM; Alvarez-Urturi C; Torras X; Balanzó J; Guarner C
    Gastroenterology; 2009 Jul; 137(1):119-28. PubMed ID: 19344721
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transjugular intrahepatic portosystemic shunt: short-term and long-term effects on hepatic and systemic hemodynamics in patients with cirrhosis.
    Lotterer E; Wengert A; Fleig WE
    Hepatology; 1999 Mar; 29(3):632-9. PubMed ID: 10051460
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hemodynamic effects of alpha-adrenergic blockade with prazosin in cirrhotic patients with portal hypertension.
    Albillos A; Lledó JL; Bañares R; Rossi I; Iborra J; Calleja JL; Garrido A; Escartin P; Bosch J
    Hepatology; 1994 Sep; 20(3):611-7. PubMed ID: 7915703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hemodynamic effects of a combination of prazosin and terlipressin in patients with viral cirrhosis.
    Lee WC; Lin HC; Yang YY; Hou MC; Lee FY; Chang FY; Lee SD
    Am J Gastroenterol; 2001 Apr; 96(4):1210-6. PubMed ID: 11316172
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of bolus injections and continuous infusions of somatostatin and placebo in patients with cirrhosis: a double-blind hemodynamic investigation.
    Cirera I; Feu F; Luca A; García-Pagán JC; Fernández M; Escorsell A; Bosch J; Rodés J
    Hepatology; 1995 Jul; 22(1):106-11. PubMed ID: 7601400
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insulin resistance in patients with cirrhosis and portal hypertension.
    Erice E; Llop E; Berzigotti A; Abraldes JG; Conget I; Seijo S; Reverter E; Albillos A; Bosch J; García-Pagán JC
    Am J Physiol Gastrointest Liver Physiol; 2012 Jun; 302(12):G1458-65. PubMed ID: 22492691
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Evaluation of propranolol response by catheterization and Doppler ultrasonography in patients with cirrhosis].
    Castaño G; Viudez P; Carlevaro O; Ocampo C; Zandalazini H; Riccitelli M; Sookoian S; Frider B
    Acta Gastroenterol Latinoam; 1998; 28(4):291-7. PubMed ID: 10347683
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of losartan, an angiotensin II receptor antagonist, on portal pressure in cirrhosis.
    Schneider AW; Kalk JF; Klein CP
    Hepatology; 1999 Feb; 29(2):334-9. PubMed ID: 9918907
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hemodynamic study during transdermal application of nitroglycerin tape in patients with cirrhosis.
    Iwao T; Toyonaga A; Sumino M; Takagi K; Ohkubo K; Inoue R; Tanikawa K
    Hepatology; 1991 Jan; 13(1):124-8. PubMed ID: 1899080
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.